GLOW (GHK-Cu + BPC-157 +…Vial · 70 mg
Mon–Fri 9:00–19:00, Sat 10:00–15:00
Vial · 10 mg
A long-acting amylin analogue. In clinical development.
Cagrilintide is a long-acting synthetic analogue of the hormone amylin developed by Novo Nordisk. Amylin is produced in the pancreas together with insulin and helps regulate satiety.
It is being studied for obesity, alone and in combination with semaglutide (CagriSema). In December 2025 Novo Nordisk submitted CagriSema to the FDA for approval.
| Component | Amount |
|---|---|
| Cagrilintide | 10 mg / vial |
Lyophilized powder for preparing a solution. Sold for scientific and laboratory research.
Documents for this batch will appear here soon.
All store certificates →